Transarterial (Chemo-)Embolization and Lipiodolization for Hepatic Haemangioma

Alicia Furumaya; Belle V. van Rosmalen; R. Bart Takkenberg; Otto M. van Delden; Cornelis H. C. Dejong; Joanne Verheij; Thomas M. van Gulik

doi:10.1007/s00270-019-02169-x

Transarterial (Chemo-)Embolization and Lipiodolization for Hepatic Haemangioma

Alicia Furumaya, Belle V. van Rosmalen^*, R. Bart Takkenberg, Otto M. van Delden, Cornelis H. C. Dejong, Joanne Verheij, Thomas M. van Gulik

^*Corresponding author for this work

Research output: Contribution to journal › (Systematic) Review article › peer-review

Abstract

BackgroundTransarterial (chemo-)embolization/lipiodolization (TAE/TAL) might be an attractive minimally invasive alternative to surgery in the treatment of symptomatic hepatic haemangioma. This review assesses the efficacy and safety of TAE/TAL as primary treatment for symptomatic hepatic haemangioma.MethodsA systematic search of the literature was performed by two reviewers following the PRISMA guidelines. Cohort studies and case reports were identified; outcomes of cohort studies were reported. The primary efficacy outcome was tumour size before and after TAE/TAL. Improvement of symptoms and quality of life (QoL) were secondary outcomes; the primary safety outcome was complications. The Downs and Black statement was used for quality assessment.ResultsEighteen cohort studies were identified, including 1284 patients. TAE/TAL led to a decrease in tumour size in 1100/1223 (89.9%) patients and to improvement or disappearance of symptoms in 1080/1096 (98.5%) patients. A significant decrease in tumour size from 9.790.79cm to 4.00 +/- 1.36cm (p

Original language	English
Pages (from-to)	800-811
Number of pages	12
Journal	Cardiovascular and Interventional Radiology
Volume	42
Issue number	6
DOIs	https://doi.org/10.1007/s00270-019-02169-x
Publication status	Published - Jun 2019

Keywords

Hepatic haemangioma
Benign liver tumour
Lipidolization
Transarterial chemoembolization
Embolization
Interventional radiology
TRANSCATHETER ARTERIAL EMBOLIZATION
CAVERNOUS HEMANGIOMAS
GIANT HEMANGIOMA
LIVER HEMANGIOMA
FOLLOW-UP
MANAGEMENT
TUMORS
CRITERIA
DIAGNOSIS
QUALITY

Access to Document

10.1007/s00270-019-02169-xLicence: CC BY

Cite this

@article{8333356653654a858806dc9f8cd5e40a,

title = "Transarterial (Chemo-)Embolization and Lipiodolization for Hepatic Haemangioma",

abstract = "BackgroundTransarterial (chemo-)embolization/lipiodolization (TAE/TAL) might be an attractive minimally invasive alternative to surgery in the treatment of symptomatic hepatic haemangioma. This review assesses the efficacy and safety of TAE/TAL as primary treatment for symptomatic hepatic haemangioma.MethodsA systematic search of the literature was performed by two reviewers following the PRISMA guidelines. Cohort studies and case reports were identified; outcomes of cohort studies were reported. The primary efficacy outcome was tumour size before and after TAE/TAL. Improvement of symptoms and quality of life (QoL) were secondary outcomes; the primary safety outcome was complications. The Downs and Black statement was used for quality assessment.ResultsEighteen cohort studies were identified, including 1284 patients. TAE/TAL led to a decrease in tumour size in 1100/1223 (89.9%) patients and to improvement or disappearance of symptoms in 1080/1096 (98.5%) patients. A significant decrease in tumour size from 9.790.79cm to 4.00 +/- 1.36cm (p",

keywords = "Hepatic haemangioma, Benign liver tumour, Lipidolization, Transarterial chemoembolization, Embolization, Interventional radiology, TRANSCATHETER ARTERIAL EMBOLIZATION, CAVERNOUS HEMANGIOMAS, GIANT HEMANGIOMA, LIVER HEMANGIOMA, FOLLOW-UP, MANAGEMENT, TUMORS, CRITERIA, DIAGNOSIS, QUALITY",

author = "Alicia Furumaya and {van Rosmalen}, {Belle V.} and Takkenberg, {R. Bart} and {van Delden}, {Otto M.} and Dejong, {Cornelis H. C.} and Joanne Verheij and {van Gulik}, {Thomas M.}",

note = "Publisher Copyright: {\textcopyright} 2019, The Author(s).",

year = "2019",

month = jun,

doi = "10.1007/s00270-019-02169-x",

language = "English",

volume = "42",

pages = "800--811",

journal = "Cardiovascular and Interventional Radiology",

issn = "0174-1551",

publisher = "Springer, Cham",

number = "6",

}

TY - JOUR

T1 - Transarterial (Chemo-)Embolization and Lipiodolization for Hepatic Haemangioma

AU - Furumaya, Alicia

AU - van Rosmalen, Belle V.

AU - Takkenberg, R. Bart

AU - van Delden, Otto M.

AU - Dejong, Cornelis H. C.

AU - Verheij, Joanne

AU - van Gulik, Thomas M.

PY - 2019/6

Y1 - 2019/6

N2 - BackgroundTransarterial (chemo-)embolization/lipiodolization (TAE/TAL) might be an attractive minimally invasive alternative to surgery in the treatment of symptomatic hepatic haemangioma. This review assesses the efficacy and safety of TAE/TAL as primary treatment for symptomatic hepatic haemangioma.MethodsA systematic search of the literature was performed by two reviewers following the PRISMA guidelines. Cohort studies and case reports were identified; outcomes of cohort studies were reported. The primary efficacy outcome was tumour size before and after TAE/TAL. Improvement of symptoms and quality of life (QoL) were secondary outcomes; the primary safety outcome was complications. The Downs and Black statement was used for quality assessment.ResultsEighteen cohort studies were identified, including 1284 patients. TAE/TAL led to a decrease in tumour size in 1100/1223 (89.9%) patients and to improvement or disappearance of symptoms in 1080/1096 (98.5%) patients. A significant decrease in tumour size from 9.790.79cm to 4.00 +/- 1.36cm (p

AB - BackgroundTransarterial (chemo-)embolization/lipiodolization (TAE/TAL) might be an attractive minimally invasive alternative to surgery in the treatment of symptomatic hepatic haemangioma. This review assesses the efficacy and safety of TAE/TAL as primary treatment for symptomatic hepatic haemangioma.MethodsA systematic search of the literature was performed by two reviewers following the PRISMA guidelines. Cohort studies and case reports were identified; outcomes of cohort studies were reported. The primary efficacy outcome was tumour size before and after TAE/TAL. Improvement of symptoms and quality of life (QoL) were secondary outcomes; the primary safety outcome was complications. The Downs and Black statement was used for quality assessment.ResultsEighteen cohort studies were identified, including 1284 patients. TAE/TAL led to a decrease in tumour size in 1100/1223 (89.9%) patients and to improvement or disappearance of symptoms in 1080/1096 (98.5%) patients. A significant decrease in tumour size from 9.790.79cm to 4.00 +/- 1.36cm (p

KW - Hepatic haemangioma

KW - Benign liver tumour

KW - Lipidolization

KW - Transarterial chemoembolization

KW - Embolization

KW - Interventional radiology

KW - TRANSCATHETER ARTERIAL EMBOLIZATION

KW - CAVERNOUS HEMANGIOMAS

KW - GIANT HEMANGIOMA

KW - LIVER HEMANGIOMA

KW - FOLLOW-UP

KW - MANAGEMENT

KW - TUMORS

KW - CRITERIA

KW - DIAGNOSIS

KW - QUALITY

U2 - 10.1007/s00270-019-02169-x

DO - 10.1007/s00270-019-02169-x

M3 - (Systematic) Review article

C2 - 30783780

SN - 0174-1551

VL - 42

SP - 800

EP - 811

JO - Cardiovascular and Interventional Radiology

JF - Cardiovascular and Interventional Radiology

IS - 6

ER -